© 1997 American Heart Association, Inc.
Articles |
Heterogeneity of Endothelial Cells
Specific Markers
From the Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy.
Correspondence to Cecilia Garlanda, Dipartimento di Immunologia e Biologia Cellulare, Istituto di Ricerche Farmacologiche Mario Negri, viale Eritrea 57, 20157 Milano, Italy. E-mail garlanda{at}irfmn.mnegri.it
 |
Abstract |
|---|
 Top Abstract IntroductionEC MarkersHighly Specialized EndotheliumECs in PathologyEndothelium-Specific PromotersConclusionsReferences |
|---|
Abstract During embryonic development, endothelial cells differentiate from a common precursor called angioblast and acquire organ-specific properties. One of the important determinants of endothelial cell differentiation is the local environment, and especially the interaction with surrounding cells. This interaction may occur through the release of soluble cytokines, cell-to-cell adhesion and communication, and the synthesis of matrix proteins on which the endothelium adheres and grows. The acquisition and maintenance of specialized properties by endothelial cells is important in the functional homeostasis of the different organs. For instance, in the brain, alteration of the blood-brain barrier properties may have important consequences on brain functional integrity. One of the major limitations to the study of endothelial cell heterogeneity is the fact that these cells are still difficult to isolate and culture from the microcirculation of different organs, and once in culture, they tend to lose their specialized properties. This finding suggests that we have to develop new culture systems, which possibly include coculture with other cell types. An important issue is to develop tools that can help in recognizing endothelial cells and their differentiated phenotype both in vivo and in tissue culture. In this review we give a short overview of the differentiated properties of the endothelium, considering a few examples of highly specialized endothelial cells, such as the brain or bone marrow microcirculation or high endothelial venules. We made a particular effort to list the most common markers of endothelial cell phenotypes. These molecules and related antibodies may be valuable tools for endothelial cell isolation and characterization.
Key Words: endothelial cells • cytokines • angiogenesis • blood-brain barrier • tumors • promoters
|
Introduction |
|---|
|
TopAbstractIntroductionEC MarkersHighly Specialized EndotheliumECs in PathologyEndothelium-Specific PromotersConclusionsReferences |
|---|
The endothelium is considered a sparse organ system, due to its vast extension and ability to exert a complex array of specialized functions.1 2 A unique characteristic of ECs is that, although they present many common functional and morphological features, they also display remarkable heterogeneity in different organs. Even in the same organ, the endothelium of large and small vessels, veins, and arteries exhibits significant heterogeneity. An extreme case is the kidney, which contains different types of ECs: fenestrated in the peritubular capillaries, discontinuous in glomerular capillaries, and continuous in other regions.2
An important and still incompletely solved question is how ECs take different pathways of differentiation. One of the determinants is the local environment in which ECs differentiate, and especially their interaction with surrounding cells. This interaction may occur through the release of soluble mediators, cell-to-cell adhesion, and the synthesis and organization of matrix proteins on which the endothelium adheres and grows.
Embryonic ECs seem particularly "plastic." Most of the specialized characteristics of ECs are induced during development, whereas adult endothelium is not equally susceptible to differentiation factors.2 3
Despite its stable constitutive properties, the adult endothelium can reversibly change its functions on activation. In a simplified view, adult ECs might be considered like small computers that can be reprogrammed according to the transitory needs of the organism.4 For instance, exposure of ECs to inflammatory cytokines, such as IL-1 and tumor necrosis factor, or to growth factors, such as VEGF or FGF, induces a complex functional reprogramming, which implies the neosynthesis of some genes and the repression of others. ECs can be activated several times during their life span by the same or different cytokines and thereby display different and reversible phenotypes.4
Cell senescence may also influence endothelial responses. Unlike young endothelium, senescent ECs display different properties, such as an inability to properly respond to growth factors due to defective signaling pathways.5 The actual mechanism regulating cell senescence is still incompletely understood; current research suggests a correlation between senescence and intracellular IL-1 accumulation.6
ECs are also functionally different when sparse and confluent cell cultures are compared. Establishment of cell-to-cell contacts inhibits both spontaneous and growth factor–induced cell growth.7 Other properties, such as arachidonic acid metabolism or release of lytic enzymes or growth factors, are changed by the establishment of intercellular contacts.8 9 10 11 We still do not know which are the intracellular mechanisms that regulate the confluent versus sparse cell phenotype. However, molecules at intercellular junctions may transfer intracellular signals that allow the cells to "sense" their neighbors and to react accordingly.7
|
EC Markers |
|---|
|
TopAbstractIntroductionEC MarkersHighly Specialized EndotheliumECs in PathologyEndothelium-Specific PromotersConclusionsReferences |
|---|
ECs express specific markers that are very helpful in identifying these cells in vivo and in culture. In many cases these molecules have been discovered through monoclonal antibodies directed to ECs. Table 1
reports a summary of most of the
identified markers (see also References 12 through 3012 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 ), while Table 2 reports a list of the antibodies used
to characterize ECs that still have unknown antigens (see References 31
through 3531 32 33 34 35 ). Interestingly, most of the markers are present on both
ECs and hemopoietic precursors or mature blood cells, reinforcing the
idea of a common embryonic precursor.2
|
|
Some of the endothelial markers are constitutive and
present in essentially all types of endothelium.
Other molecules are expressed only after activation by inflammatory
cytokines or growth factors (see Table 3 and References 36 through 4036 37 38 39 40 ).
|
Some markers are rather specific for ECs of different origins (Table 4 and References 41 through 4641 42 43 44 45 46 ). However,
this last category is relatively scarce, possibly because EC isolation
from the microvasculature of certain vascular regions is still
experimentally difficult. New techniques are under development, such as
the injection of phage-display peptide libraries,47 48
which detect specific surface molecules in the peripheral
endothelium in vivo. Other alternatives to study
microvascular endothelium are (1) the culture of ECs
from different organs by implanting sponges containing angiogenic
factors that promote infiltration of the ECs from that particular
site49 and (2) the isolation of ECs after organ disruption
through the use of magnetic beads coated with
anti-endothelial antibodies.50
|
It is not unusual that the same protein may be expressed, with different degrees and types of glycosylation, in different vascular regions. This finding may lead to the development of tissue-specific monoclonals that, despite recognizing the same antigen, are capable of discriminating between tissue-specific glycosylation patterns.
EC marker expression is also related to the functional needs of the cells during vascular morphogenesis in the embryo. In an in vitro model of vasculogenesis, it was found that ECs, as the hemopoietic precursors, go through different stages of differentiation.51 Initially, they express flk-1/KDR, which is one of the receptors for VEGF, and PECAM-1, followed in sequence by Tie-2, Tie-1, and vascular endothelial cadherin. This observation implies that ECs with an intermediate phenotype may exist. Along this line, a recent study describes the presence of EC precursors in the blood of adult individuals.52 At the time of isolation, these cells express flk-1/KDR and only when kept in culture were they able to upregulate PECAM-1, Tie-2, or E-selectin.
|
Highly Specialized Endothelium |
|---|
|
TopAbstractIntroductionEC MarkersHighly Specialized EndotheliumECs in PathologyEndothelium-Specific PromotersConclusionsReferences |
|---|
As discussed above, there are several examples of specialized ECs. In this review, we selected three types of endothelium of particular biological relevance and on which a relatively large amount of information is available. These are (1) the high endothelium present in the postcapillary venules of lymph nodes and Peyer's patches, (2) the endothelium of the bone marrow, and (3) the endothelium of the brain.
HEVs
Lymphocytes continuously recirculate from blood to lymphatic or
peripheral tissues and vice versa.53 54 Naive
and memory lymphocytes follow separate pathways in this
process55 : naive lymphocytes mainly recirculate by
emigrating through HEVs in peripheral lymphatic tissues and
then through efferent lymph and the thoracic duct back to blood. Memory
lymphocytes recirculate through postcapillary venules in those
peripheral tissues (for example, skin or mucosal tissues)
in which they first encountered the antigen.54 The
specificity of the emigration process is determined and sustained by EC
specialization,56 by the expression of different
combinations of adhesion molecules, and by the production of
specific chemokines.57 58
HEVs are present in all peripheral lymphatic tissues, including lymph nodes and lymphatic tissues associated with the digestive tract and respiratory tree. However, in chronically inflamed tissues, such as skin, gut, or synovium, ECs from the venules may acquire HEV-like characteristics.53
In lymph nodes deprived of afferent lymph, HEVs lose their phenotype and assume a flat morphology.59 60 The inducibility and reversibility of their characteristics suggest that the local environment may be involved in HEV specialization. Antigens drained from peripheral tissues through the lymphatic circulation, along with cytokines produced by lymphocytes and interdigitating dendritic cells,59 are believed to induce HEV features. Another environmental factor involved in HEV differentiation is the extracellular matrix. Hevin is a recently cloned matrix protein61 that is highly expressed in HEVs of human lymphoid tissues. Hevin is structurally and functionally related to SPARC, an antiadhesive acidic glycoprotein. Like SPARC, hevin is antiadhesive. Hevin association with the basal, lateral, and luminal sides of HEV membranes might weaken endothelial cell-to-cell and cell-to-matrix adhesion and facilitate lymphocyte motility and emigration.61
HEVs differ from ECs of other small vessels with respect to morphology
and functional properties: (1) They have an almost cuboidal cellular
morphology; (2) their metabolic apparatus,
Golgi complex, rough endoplasmic reticulum, and
polyribosomes are particularly developed56 ;
(3) they present, on their luminal surface, a prominent
glycocalyx56 ; and (4) like postcapillary venules, they
have discontinuous cell-to-cell junctions and essentially no or very
poorly organized tight junctions.62 Most importantly, HEVs
constitutively express counterreceptors for lymphocyte adhesion
molecules that cannot be found elsewhere. One group of these molecules,
named peripheral node addressins, was identified for its
reactivity with the mAb MECA 79, which recognizes a carbohydrate
epitope common among these proteins63 (Table 4
).
Some of the molecules expressing the MECA 79 epitope are L-selectin counterreceptors. L-selectin is expressed by all normal naive T and B cells and is required for lymphocytes to enter into lymph nodes from the blood.64 MECA 79 can inhibit the interaction between lymphocytes and HEVs.63 MECA 79 immunoprecipitates 7 to 10 bands from mouse peripheral lymph node HEVs, of which only four are recognized by L-selectin.64 These are Sgp 50, or GlyCAM-1,65 Sgp 90, a specifically posttranslational modified form of CD34,66 Sgp 200, which has not been molecularly identified yet, and MAdCAM-1, which is mostly found on HEVs of mucosal lymph nodes and Peyer's patches.67
When expressed by HEVs, MECA 79 proteins are specifically glycosylated
with O-linked oligosaccharides, of which the
prototype is sialyl–LewisX. The presence of sialic acid
residues, sulfation, and 
(1,3)fucosylation of
oligosaccharides are critical for L-selectin
recognition.68
None of these molecules are HEV specific. MECA 79 specificity is
related to posttranslational modifications of the antigens. In
particular, MECA 79 recognizes serine- and/or threonine-linked
oligosaccharides, which may present antigenic properties
specific for HEVs. Interestingly, the expression of mouse
(1,3)fucosyltransferase correlates with the expression of L-selectin
binding sites in HEVs.69 The binding specificity of such
common carbohydrate residues might also be due to the diverse
combinations of spacing and clustering displayed by these chains on the
protein backbone.68
After the attachment of L-selectin to its counterreceptors during the
rolling phase and after chemokine activation, lymphocyte arrest is
mediated by activated LFA-1 and its counterreceptors ICAM-1 and
ICAM-2 and by 4ß7 and its counterreceptor MAdCAM-1. MAdCAM-1 can
function both as a selectin and integrin ligand as a result of its
mucinlike and Ig-like domains.67 In contrast to the
classical emigration process in postcapillary venules, the coupled
4ß1–VCAM-1 is not involved, due to the lack of expression of
VCAM-1 by HEVs.70
VAP-1 is an endothelial molecule constitutively expressed on the surface membrane and in cytoplasmic granules of HEVs and a subset of ECs of normal and inflamed tissues, where it participates in lymphocyte recruitment.71 72 Knowledge about VAP-1 is still very scant, owing to its ligand and the stimuli able to induce its expression at sites of inflammation, which remain unidentified. VAP-1 expression in umbilical vein ECs is present only in cytoplasmic granules, where the molecule lacks sialic acid residues that are present in HEVs and essential for lymphocyte adhesion.73
Lymphocytes recirculating in peripheral tissues do not use specialized structures like HEVs. However, during chronic inflammation, microvascular structures assume HEV-like properties and allow lymphocyte infiltration.53
E-selectin plays an important role during cases of skin inflammation.74 E-selectin is transiently expressed on umbilical vein endothelium after activation by inflammatory cytokines but is more persistent in ECs from chronically inflamed tissues.64
The E-selectin counterreceptor for lymphocytes infiltrating the dermis is CLA-1.75 While only 2% to 3% of peripheral blood cells express the glycoprotein CLA-1, 80% of skin lymphocytes are CLA-1 positive, suggesting that E-selectin functions as a skin homing receptor. Besides the E-selectin–CLA-1 pair, MECA 79 reactivity63 and sialylated VAP-176 are strongly induced in the skin microvasculature in several pathological conditions and sustain lymphocyte binding and infiltration.
Bone Marrow ECs
Proliferation, differentiation, and maturation of hemopoietic
cells are influenced and controlled by the bone marrow
microenvironment. Bone marrow stroma is composed of different cell
types, such as fibroblasts, ECs, adipocytes, osteoblasts, reticular
cells, and monocytes. These cells produce cytokines and
synthesize matrix proteins that can influence the growth and maturation
of the hemopoietic precursors. The endothelium is
located among stromal cells at the interface between the blood and bone
marrow environment. These cells actively participate in hemopoiesis and
in regulating the transit of both precursors and mature blood cells
between the bone marrow and the circulation.77
During embryogenesis, hemopoiesis begins in the extraembryonic blood islands of the yolk sac and in the intraembryonic aorta-gonad-mesonephron region.78 Later, the fetal liver and finally the bone marrow are the sites where the hemopoietic system develops. The yolk sac blood islands are simple structures in which CD34+ hemopoietic cells in the middle are in close contact with CD34+ ECs confined at the periphery.79 These structures produce pluripotential hemopoietic stem cells.80 The endothelium of the blood islands produces important amounts of hemopoietic cytokines, such as stem cell factor; flk-2/flt-3 ligand; leukemia inhibitory factor; and IL-6 macrophage-CSF, granulocyte/macrophage-CSF, and granulocyte-CSF. This observation supports the hypothesis that these cells are major effectors in controlling hemopoiesis in the yolk sac.78
ECs from human bone marrow have been isolated and characterized.81 These cells are able to promote long-term multilineage hemopoiesis, particularly myelopoiesis and megakariocytopoiesis.82 In addition to bone marrow endothelium, umbilical vein ECs are also capable of producing cytokines that influence hemopoiesis. These include IL-1, IL-4, and IL-6 granulocyte/macrophage-CSF, granulocyte-CSF, and macrophage-CSF; stem cell factor after stimulation with inflammatory stimuli4 83 ; and FGF, transforming growth factor-ß, platelet-derived growth factor, and leukemia inhibitory factor in resting conditions.82 84 However, unlike umbilical vein ECs, bone marrow endothelium constitutively produces granulocyte-CSF, granulocyte/macrophage-CSF, IL-6, and kit ligand, which may be important in long-term hemopoiesis.82
Bone marrow ECs synthesize adhesion molecules on their surface, which could play an important role in controlling the traffic of hemopoietic cells from and to the blood. In contrast to umbilical vein ECs, where adhesion molecules for circulating cells are induced essentially after activation, bone marrow endothelium constitutively expresses VCAM-1 and E-selectin both in vitro and in vivo.85 86 87 88 This observation suggests that these structures might act as bone marrow endothelial addressins for the homing of hemopoietic progenitors.
Bone marrow capillaries have the morphology of discontinuous fenestrated sinusoids. The presence of discontinuities in the vessel wall might facilitate the traffic of the hemopoietic and mature blood cells.2
BBB
The endothelium of the brain microvasculature
represents the interface between blood and the central nervous
system. Due to its unique location, it has specific protective
properties that strictly regulate the infiltration of plasma components
and circulating cells into the brain. The BBB normally permits the
passage of only small hydrophobic molecules, a limited number of
specifically transported nutrients such as glucose and amino acids, and
some transcytosed molecules such as transferrin (for review, see
References 89 through 9189 90 91 ).
In general, the barrier activity is due to well-developed tight junctions between ECs, very selective intracellular transport systems, and a very low pinocytotic activity. Tight junctions are particularly well developed in brain vessels, most of which associate to the P phase of the cell membrane, indirectly indicating a close linkage to the cytoskeleton.92
The presence of such a developed system of tight junctions is probably
responsible for the well-established cell polarization found in brain
capillaries.91 Cell polarization helps to direct the
transport of solutes from the apical to the basal membrane and vice
versa. The ECs of the brain synthesize the multidrug-resistance protein
P-glycoprotein, or mdr 1a, which actively
transports a variety of low-molecular-weight molecules out of the brain
to the circulation.93 94 This reverse mechanism protects
the nervous tissue from the accumulation of undesired toxic molecules.
Brain endothelium also has specific transport systems
directing flow from the circulating blood to the brain, such as the
glucose transporter Glut-1 or a well-developed set of amino acid
transporters91 95 (Table 4).
Brain microvasculature derives from the meningeal vessels and invades the brain by angiogenesis.89 These ECs acquire the characteristics of the BBB, most likely through contact with the neuroectoderm during embryogenesis. Astrocytes contribute to the establishment of barrier properties in ECs.90 96 However, recent evidence shows that some specific markers of the brain microvasculature are already expressed by these cells as early as day 10.5 of gestation, when astrocytes are not yet detectable.94 97 This finding suggests that some forms of "early" endothelial commitment exist even in the absence of the interaction with astrocytes.98
During their differentiation, brain ECs not only acquire specific markers but also lose, or express to a low degree, molecules that are otherwise present in other types of endothelium, like MECA 32.99 100
Interestingly, the vessels that invade brain tumors, like glioblastoma multiforme, do not have BBB properties, which results in brain edema. In this type of tumor, the effect seems to be mostly due to the formation of channels through interendothelial junctions.101 This observation suggests that for maintenance of specialized barrier properties, ECs require a continuous interaction with normal nervous cells. When ECs invade a neoformed tumor, such as a glioma or glioblastoma, they come into contact with tumor cells that produce growth factors, in particular VEGF, which may be responsible not only for vascular proliferation but also for the altered permeability properties of the neoformed vessels.102 103 104
|
ECs in Pathology |
|---|
|
TopAbstractIntroductionEC MarkersHighly Specialized EndotheliumECs in PathologyEndothelium-Specific PromotersConclusionsReferences |
|---|
Tumor Vasculature
With some exceptions, such as the female reproductive cycle and wound healing, angiogenesis in the adult occurs only in response to pathogenic stimuli (for review see Reference 105105 ). The release of growth factors from tumor cells induces ECs of adjacent vessels to migrate, proliferate, and invade the developing tumor focus.106 107
An important question is whether these new vessels are different from the rest of the vasculature and whether they can be distinguished by the use of specific markers. This issue has many practical implications. One can link cytotoxic agents to monoclonal antibodies or ligands able to bind the tumor vasculature and induce its destruction without affecting other vessels or tissues.108
Tumor vessels present specific morphology, relatively uncontrolled permeability, fenestrae, and a well-developed vesicular system. This phenotype seems to be induced, at least in part, by VEGF,109 110 which is released by tumor cells (see also above).
In general, the ECs that vascularize tumors upregulate antigens, such
as the growth factor receptors flk-1/KDR, Tie-1,
Tie-2,111 112 113 the integrin vß3,114 or
the alternative spliced variant of fibronectin, ED-B,115
which otherwise are present only in the vessels of the developing
embryo. These molecules are markers of endothelial
proliferation and as such are not strictly specific for the tumor
vasculature but can be found in other angiogenic vessels.
Tumor ECs express different levels of adhesive molecules for
circulating leukocytes. More specifically, activation of ECs with VEGF
depresses and with FGF upregulates ICAM-1 and VCAM-1
levels.116 The level of E-selectin was also found to be
high in tumor capillaries, possibly due to high levels of tumor
necrosis factor-.108 Therefore, the nature of the local
environment may influence EC susceptibility to cytotoxic
leukocytes.
Leukocyte adhesive molecules are present in many types of ECs on
activation with inflammatory cytokines, and they cannot be
considered strictly specific for tumor vessels. More specific markers
for tumor endothelium are still scant and only
partially characterized (Table 4).
It is possible that not all tumor vessels are the same. It is conceivable that angiogenic ECs retain the properties of the vessels of origin and that the tumor tissue influences the functional and morphological characteristics of the invading vasculature. This raises the question of whether one can expect to find markers for the vessels of a given tumor that are not necessarily present in the vasculature of another type of tumor.
EC Tumors
ECs can acquire malignant properties. For instance, they can form
tumors such as angiosarcomas, which are highly invasive and usually
connote a lethal prognosis (for review, see Reference 117117 ).
Angiosarcomas and hemangioendotheliomas retain most of the
endothelial markers but express low amounts of vascular
endothelial cadherin.118 This is
interesting, since cadherins in general are downregulated in other
types of malignant tumors.119
The majority of data available strongly suggest that Kaposi's sarcoma has an endothelial origin. However, it expresses markers for both ECs and macrophages,118 120 suggesting that it might originate from a special type of EC similar to macrophages present in lymph nodes.
Kaposi's sarcoma cells have the specificity of producing a large set of cytokines.121 These cells express KDR but not flt-1; this finding is of interest, since flt-1 is important in vascular morphogenesis.111 122
Other types of hemangiomas have a more benign outcome. They are characterized by rapid EC growth and the formation of abnormal vascular structures. In some cases they are likely to represent malformations.117 The antigenic profile of a large variety of hemangiomas is similar to that of normal ECs,118 but hemangiomas express E-selectin constitutively.123 The abnormal vascular proliferation could be related to locally released growth factors and fibrinolytic agents rather than to structural alterations of ECs.124
For some hereditary hemangiomas, the vascular anomalies seem to be related to altered interactions between ECs and mesenchymal cells.
In two familiar mucocutaneous venous malformations,125 the endothelial tyrosine kinase receptor Tie-2 is mutated. Tie-2 is the receptor for angiopoietin,126 127 which is produced by mesenchymal cells and is important for normal vessel morphogenesis.
Hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome) has been found to be due to the mutation of two transforming growth factor-ß binding proteins: endoglin and activin-receptor–like kinase.128 129 These changes might be related to abnormal mesenchymal cell proliferation and organization around the vascular structures.
|
Endothelium-Specific Promoters |
|---|
|
TopAbstractIntroductionEC MarkersHighly Specialized EndotheliumECs in PathologyEndothelium-Specific PromotersConclusionsReferences |
|---|
The presence of EC-specific markers is related to the presence of specific expression systems.
Several endothelium-specific promoters have been described so far (a few examples are flk-1,130 Flt-1,131 Tie-2,132 von Willebrand factor,133 and endothelin-1134 ). In many cases, the promoters of endothelial genes contain the consensus motifs for Sp1, EGR-1, ets, and GATA transcription factors (eg, see Reference 135135 ). These factors are not cell specific and not in all cases have these sites been proven necessary for the expression of the gene.
Many efforts have been directed toward the definition of endothelium-specific transcription factors. It is likely that the combination of different factors confers "cell-specific" expression of genes.
Promoter sequences for endothelium-specific genes have important applications. They can be used for gene targeting in ECs, both in gene therapy and in transgenic mice.108 The possibility of constructing promoters containing endothelium-specific and inducible sequences allows the induction of the expression of a given gene at the time and condition desired.
Only a few examples exist that analyze promoter sequences specific for the endothelium of selected regions of the vascular tree.133 One of these is the von Willebrand factor promoter sequence. Using different stretches of the 5' end of the gene, one can obtain promoter sequences that act only in some regions of the vascular tree but not in others.133
|
Conclusions |
|---|
|
TopAbstractIntroductionEC MarkersHighly Specialized EndotheliumECs in PathologyEndothelium-Specific PromotersConclusionsReferences |
|---|
Understanding the molecular basis of EC heterogeneity is an important task. ECs might strongly influence the homeostasis of the different organs, and any pathological conditions in which they lose their specialized properties might have dramatic consequences. As discussed above, a typical example is the brain endothelium, whose differentiated properties are of fundamental importance in protecting the central nervous system from noxious agents.
Most of our knowledge about ECs comes from the study of human umbilical vein endothelium. These cells might not be an ideal model, since they are close to senescence and are cultured from hypoxic and possibly activated vessels.
Hopefully, in the future it will be easier to culture the endothelium from the microvasculature of different organs and to maintain their specialized properties in vitro. To this end, it is possible that complex coculture systems with different cell types will be required. The development of immortalized EC lines from different origins could also be an important tool, providing that immortalization would alter only partially the tissue-specific characteristics.
|
Selected Abbreviations and Acronyms |
|---|
|
|
Acknowledgments |
|---|
This work was supported by Associazione Italiana per la Ricerca sul Cancro, the European Community (projects CHRX-CT9.940593, Biomed 2 PL 950669, and BMH4-CT95-0875; and Biotech 960036), and Istituto Superiore di Sanità project "Sostituzioni funzionali, organi artificiali e trapianti di organo" and Special Projects AIDS. C. Garlanda is recipient of a fellowship from the Istituto Superiore di Sanità for the research on AIDS. We thank A. Mantovani, A. Vecchi, and I. Martin-Padura for many helpful discussions and suggestions.
Received March 16, 1997; accepted April 1, 1997.
|
References |
|---|
|
TopAbstractIntroductionEC MarkersHighly Specialized EndotheliumECs in PathologyEndothelium-Specific PromotersConclusionsReferences |
|---|
1. Augustin HG, Kozian DH, Johnson RC. Differentiation of endothelial cells: analysis of the constitutive and activated endothelial cell phenotypes. Bioessays. 1994;16:901-906.[Medline] [Order article via Infotrieve]
2. Risau W. Differentiation of endothelium. FASEB J. 1995;9:926-933.[Abstract]
3. Engelhardt B, Risau W. Development of the blood-brain barrier. In: Greenwood J, Begley D, Segal M, eds. New Concepts of a Blood-Brain Barrier. New York, NY: Plenum Press; 1995:11-31.
4. Mantovani A, Bussolino F, Dejana E. Cytokine regulation of endothelial cell function. FASEB J. 1992;6:2591-2599.[Abstract]
5.
Garfinkel S, Hu X, Prudovsky IA, McMahon GA, Kapnik
EM, McDowell SD, Maciag T. FGF-1–dependent proliferative and
migratory responses are impaired in senescent human umbilical vein
endothelial cells and correlate with the inability to
signal tyrosine phosphorylation of fibroblast growth
factor receptor-1 substrates. J Cell Biol. 1996;134:783-791.
6.
Garfinkel S, Brown S, Wessendorf JH, Maciag
T. Post-tran-scriptional regulation of interleukin 1 alpha in
various strains of young and senescent human umbilical vein
endothelial cells. Proc Natl Acad Sci
U S A. 1994;91:1559-1563.
7. Dejana E. Endothelial adherens junctions: implications in the control of vascular permeability and angiogenesis. J Clin Invest. 1996;98:1949-1953.[Medline] [Order article via Infotrieve]
8. Eldor A, Vlodavsky I, Hy-Am E, Atzmon R, Weksler BB, Raz A, Fuks Z. Cultured endothelial cells increase their capacity to synthesize prostacyclin following the formation of the contact inhibited cell monolayer. J Cell Physiol. 1983;114:179-183.[Medline] [Order article via Infotrieve]
9.
Isaacs J, Savion N, Gospodarowicz D, Shuman
MA. Effect of cell density on thrombin binding to a specific
site on bovine vascular endothelial cells.
J Cell Biol. 1981;90:670-674.
10. Yu ZX, Biro S, Fu YM, Sanchez J, Smale G, Sasse J, Ferrans VJ, Casscells W. Localization of basic fibroblast growth factor in bovine endothelial cells: immunohistochemical and biochemical studies. Exp Cell Res. 1993;204:247-259.[Medline] [Order article via Infotrieve]
11. Yoshizumi M, Hsieh CM, Zhou F, Tsai JC, Patterson C, Perrella MA, Lee ME. The ATF site mediates downregulation of the cyclin A gene during contact inhibition in vascular endothelial cells. Mol Cell Biol. 1995;15:3266-3272.[Abstract]
12. Belloni PN, Tressler RJ. Microvascular endothelial cell heterogeneity: interactions with leukocytes and tumor cells. Cancer Metastasis Rev. 1990;8:353-389.[Medline] [Order article via Infotrieve]
13. DeLisser HM, Newman PJ, Albelda SM. Molecular and functional aspects of PECAM-1/CD31. Immunol Today. 1994;15:490-495.[Medline] [Order article via Infotrieve]
14. Vecchi A, Garlanda C, Lampugnani MG, Resnati M, Matteucci C, Stoppacciaro A, Schnurch H, Risau W, Ruco L, Mantovani A, Dejana E. Monoclonal antibodies specific for endothelial cells of mouse blood vessels: their application in the identification of adult and embryonic endothelium. Eur J Cell Biol. 1994;63:247-254.[Medline] [Order article via Infotrieve]
15.
Voyta JC, Via DP, Butterfield CE, Zetter BR.
Identification and isolation of endothelial cells based
on their increased uptake of acetylated-low density
lipoprotein. J Cell Biol. 1984;99:2034-2040.
16.
Jackson CJ, Garbett PK, Nissen B, Schrieber L.
Binding of human endothelium to Ulex europaeus I-coated
Dynabeads: application to the isolation of microvascular
endothelium. J Cell Sci. 1990;96:257-262.
17. Sahagun G, Moore SA, Fabry Z, Schelper RL, Hart MN. Purification of murine endothelial cell cultures by flow cytometry using fluorescein-labeled griffonia simplicifolia agglutinin. Am J Pathol. 1989;134:1227-1232.[Abstract]
18.
Weibel ER, Palade G. New cytoplasmic
components in arterial endothelia. J Cell
Biol. 1964;23:101-112.
19.
Lampugnani MG, Resnati M, Raiteri M, Pigott R,
Pisacane A, Houen G, Ruco LP, Dejana E. A novel
endothelial-specific membrane protein is a marker of
cell-cell contacts. J Cell Biol. 1992;118:1511-1522.
20.
Krause DS, Fackler MJ, Civin CI, May WS. CD34:
structure, biology, and clinical utility. Blood. 1996;87:1-13.
21. Springer TA. Adhesion receptors of the immune system. Nature. 1990;346:425-434.[Medline] [Order article via Infotrieve]
22. Gougos A, Letarte M. Identification of a human endothelial cell antigen with monoclonal antibody 44G4 produced against a pre-B leukemic cell line. J Immunol. 1988;141:1925-1933.[Abstract]
23.
Greenwalt DE, Lipsky RH, Ockenhouse CF, Ikeda H,
Tandon NN, Jamieson GA. Membrane glycoprotein CD36:
a review of its roles in adherence, signal transduction, and
transfusion medicine. Blood. 1992;80:1105-1115.
24. Airas L, Salmi M, Jalkanen S. Lymphocyte–vascular adhesion protein-2 is a novel 70-kDa molecule involved in lymphocyte adhesion to vascular endothelium. J Immunol. 1993;151:4228-4238.[Abstract]
25. Bardin N, Frances V, Lesaule G, Horschowski N, George F, Sampol J. Identification of the S-Endo 1 endothelial-associated antigen. Biochem Biophys Res Commun. 1996;218:210-216.[Medline] [Order article via Infotrieve]
26. Esmon CT. Thrombomodulin as a model of molecular mechanisms that modulate protease specificity and function at the vessel surface. FASEB J. 1995;9:946-955.[Abstract]
27.
Vainio O, Dunon D, Aissi F, Dangy JP, McNagny KM,
Imhof BA. HEMCAM, an adhesion molecule expressed by c-kit+
hemopoietic progenitors. J Cell Biol. 1996;135:1655-1668.
28.
Yamamoto Y, Yasumizu R, Amou Y, Watanabe N, Nishio N,
Toki J, Fukuhara S, Ikehara S. Characterization of
peripheral blood stem cells in mice.
Blood. 1996;88:445-454.
29.
Beckner ME, Krutzsch HC, Stracke ML, Williams ST,
Gallardo JA, Liotta LA. Identification of a new immunoglobulin
superfamily protein expressed in blood vessels with a heparin-binding
consensus sequence. Cancer Res. 1995;55:2140-2149.
30. Schlossmann SF, Boumsell L, Gilks W, Harland JM, Kishimoto T, Morimoto C, Ritz J, Shaw S, Silverstein R, Springer T, Tedder TF, Todd RF, eds. Leucocyte Typing, V: White Cell Differentiation Antigens. New York, NY: Oxford University Press; 1995.
31. Schlingemann RO, Dingjan GM, Emeis JJ, Blok J, Warnaar SO, Ruiter DJ. Monoclonal antibody PAL-E specific for endothelium. Lab Invest. 1985;52:71-76.[Medline] [Order article via Infotrieve]
32.
Goerdt S, Walsh LJ, Murphy GF, Pober JS.
Identification of a novel high molecular weight protein preferentially
expressed by sinusoidal endothelial cells in normal
human tissues. J Cell Biol. 1991;113:1425-1437.
33. Schlingemann RO, Rietveld FJ, Kwaspen F, van de Kerkhof PC, De Waal RM, Ruiter DJ. Differential expression of markers for endothelial cells, pericytes, and basal lamina in the microvasculature of tumors and granulation tissue. Am J Pathol. 1991;138:1335-1347.[Abstract]
34. Hagemeier HH, Vollmer E, Goerdt S, Schulze Osthoff K, Sorg C. A monoclonal antibody reacting with endothelial cells of budding vessels in tumors and inflammatory tissues, and non-reactive with normal adult tissues. Int J Cancer. 1986;38:481-488.[Medline] [Order article via Infotrieve]
35.
Pardanaud L, Altmann C, Kitos P, Dieterlen Lievre F,
Buck CA. Vasculogenesis in the early quail blastodisc as studied
with a monoclonal antibody recognizing endothelial
cells. Development. 1987;100:339-349.
36.
Quinn TP, Peters KG, De Vries C, Ferrara N, Williams
LT. Fetal liver kinase 1 is a receptor for vascular
endothelial growth factor and is selectively expressed
in vascular endothelium. Proc Natl Acad
Sci U S A. 1993;90:7533-7537.
37.
Peters KG, De Vries C, Williams LT. Vascular
endothelial growth factor receptor expression during
embryogenesis and tissue repair suggests a role in
endothelial differentiation and blood vessel
growth. Proc Natl Acad Sci U S A. 1993;90:8915-8919.
38.
Mustonen T, Alitalo K.
Endothelial receptor tyrosine kinases involved in
angiogenesis. J Cell Biol. 1995;129:895-898.
39.
Rettig WJ, Garin Chesa P, Healey JH, Su SL, Jaffe EA,
Old LJ. Identification of endosialin, a cell surface
glycoprotein of vascular endothelial cells
in human cancer. Proc Natl Acad Sci U S A. 1992;89:10832-10836.
40. Eichmann A, Marcelle C, Bréant C, Le Douarin NM. Two molecules related to the VEGF receptor are expressed in early endothelial cells during avian embryonic development. Mech Dev. 1993;42:33-48.[Medline] [Order article via Infotrieve]
41.
Kaipainen A, Korhonen J, Mustonen T, van Hinsbergh
VW, Fang GH, Dumont D, Breitman M, Alitalo K. Expression of the
fms-like tyrosine kinase 4 gene becomes restricted to lymphatic
endothelium during development. Proc Natl
Acad Sci U S A. 1995;92:3566-3570.
42. Schmelz M, Franke WW. Complexus adhaerentes, a new group of desmoplakin-containing junctions in endothelial cells: the syndesmos connecting retothelial cells of lymph nodes. Eur J Cell Biol. 1993;61:274-289.[Medline] [Order article via Infotrieve]
43. Valiron O, Chevrier V, Usson Y, Breviario F, Job D, Dejana E. Desmoplakin expression and organization at human umbilical vein endothelial cell-to-cell junctions. J Cell Sci. 1996;109:2141-2149.[Abstract]
44. Goetz DJ, el Sabban ME, Hammer DA, Pauli BU. Lu-ECAM-1–mediated adhesion of melanoma cells to endothelium under conditions of flow. Int J Cancer. 1996;65:192-199.[Medline] [Order article via Infotrieve]
45. Jefferies WA, Brandon MR, Hunt SV, Williams AF, Gatter KC, Mason DY. Transferrin receptor on endothelium of brain capillaries. Nature. 1984;312:162-163.[Medline] [Order article via Infotrieve]
46. Seulberger H, Lottspeich F, Risau W. The inducible blood-brain barrier specific molecule HT7 is a novel immunoglobulin-like cell surface glycoprotein. EMBO J. 1990;9:2151-2158.[Medline] [Order article via Infotrieve]
47. Kozian DH, Augustin HG. Rapid identification of differentially expressed endothelial cell genes by RNA display. Biochem Biophys Res Commun. 1995;209:1068-1075.[Medline] [Order article via Infotrieve]
48. Pasqualini R, Ruoslahti E. Organ targeting in vivo using phage display peptide libraries. Nature. 1996;380:364-366.[Medline] [Order article via Infotrieve]
49. MacPhee MJ, Wiltrout RH, McCormick KL, Sayers TJ, Pilaro AM. A method for obtaining and culturing large numbers of purified organ-derived murine endothelial cells. J Leukoc Biol. 1994;55:467-475.[Abstract]
50. Dong QG, Bernasconi S, Lostaglio S, Wainstok de Calmanovici R, Martin Padura I, Breviario F, Garlanda C, Ramponi S, Mantovani A, Vecchi A. A general strategy for isolation of endothelial cells from murine tissues: characterization of two endothelial cell lines obtained from murine lung and subcutaneous sponge implants. Arterioscler Thromb Vasc Biol. 1997. In press.
51.
Vittet D, Prandini MH, Berthier R, Schweitzer A,
Martin-Sisteron H, Uzan G, Dejana E. Embryonic stem cells
differentiate in vitro to endothelial cells through
successive maturation steps. Blood. 1996;88:3424-3431.
52.
Asahara T, Murohara T, Sullivan A, Silver M, van der
Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM. Isolation
of putative progenitor endothelial cells for
angiogenesis. Science. 1997;275:964-967.
53. Picker LJ, Butcher EC. Physiological and molecular mechanisms of lymphocyte homing. Annu Rev Immunol. 1992;10:561-591.[Medline] [Order article via Infotrieve]
54. Springer TA. Traffic signal for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell. 1994;76:301-314.[Medline] [Order article via Infotrieve]
55.
Mackay CR, Marston WL, Dudler L. Naive and
memory T cells show distinct pathways of lymphocyte
recirculation. J Exp Med. 1990;171:801-817.
56. Girard JP, Springer TA. High endothelial venules (HEVs): specialized endothelium for lymphocyte migration. Immunol Today. 1995;16:449-457.[Medline] [Order article via Infotrieve]
57. Brown Z, Gerritsen ME, Carley WW, Strieter RM, Kunkel SL, Westwick J. Chemokine gene expression and secretion by cytokine-activated human microvascular endothelial cells: differential regulation of monocyte chemoattractant protein-1 and interleukin-8 in response to interferon-gamma. Am J Pathol. 1994;145:913-921.[Abstract]
58. Sozzani S, Locati M, Allavena P, Van Damme J, Mantovani A. Chemokines: a superfamily of chemotactic cytokines. Int J Clin Lab Res. 1996;26:69-82.[Medline] [Order article via Infotrieve]
59.
Mebius RE, Streeter PR, Breve J, Duijvestijn AM,
Kraal G. The influence of afferent lymphatic vessel interruption
on vascular addressin expression. J Cell Biol. 1991;115:85-95.
60. Mebius RE, Dowbenko D, Williams A, Fennie C, Lasky LA, Watson SR. Expression of GlyCAM-1, an endothelial ligand for L-selectin, is affected by afferent lymphatic flow. J Immunol. 1993;151:6769-6776.[Abstract]
61.
Girard JP, Springer TA. Modulation of
endothelial cell adhesion by hevin, an acidic protein
associated with high endothelial venules.
J Biol Chem. 1996;271:4511-4517.
62. Anderson AO, Shaw S. T cell adhesion to endothelium: the FRC conduit system and other anatomic and molecular features which facilitate the adhesion cascade in lymph node. Semin Immunol. 1993;5:271-282.[Medline] [Order article via Infotrieve]
63. Michie SA, Streeter PR, Bolt PA, Butcher EC, Picker LJ. The human peripheral lymph node vascular addressin: an inducible endothelial antigen involved in lymphocyte homing. Am J Pathol. 1993;143:1688-1698.[Abstract]
64.
Kansas GS. Selectins and their ligands:
current concepts and controversies. Blood. 1996;88:3259-3287.
65. Lasky LA, Singer MS, Dowbenko D, Imai Y, Henzel WJ, Grimley C, Fennie C, Gillett N, Watson SR, Rosen SD. An endothelial ligand for L-selectin is a novel mucin-like molecule. Cell. 1992;69:927-938.[Medline] [Order article via Infotrieve]
66.
Baumheter S, Singer MS, Henzel W, Hemmerich S, Renz
M, Rosen SD, Lasky LA. Binding of L-selectin to the vascular
sialomucin CD34. Science. 1993;262:436-438.
67. Berg EL, McEvoy LM, Berlin C, Bargatze RF, Butcher EC. L-selectin–mediated lymphocyte rolling on MAdCAM-1. Nature. 1993;366:695-698.[Medline] [Order article via Infotrieve]
68.
Varki A. Selectin ligands. Proc
Natl Acad Sci U S A. 1994;91:7390-7397.
69.
Smith PL, Gersten KM, Petryniak B, Kelly RJ, Rogers
C, Natsuka Y, Alford JA, Scheidegger EP, Natsuka S, Lowe JB.
Expression of the alpha(1,3)fucosyltransferase Fuc-TVII in lymphoid
aggregate high endothelial venules correlates with
expression of L-selectin ligands. J Biol Chem. 1996;271:8250-8259.
70. Hahne M, Lenter M, Jager U, Isenmann S, Vestweber D. VCAM-1 is not involved in LPAM-1 (alpha 4 beta p/alpha 4 beta 7) mediated binding of lymphoma cells to high endothelial venules of mucosa-associated lymph nodes. Eur J Cell Biol. 1993;61:290-298.[Medline] [Order article via Infotrieve]
71.
Salmi M, Jalkanen S. A 90-kilodalton
endothelial cell molecule mediating lymphocyte binding
in humans. Science. 1992;257:1407-1409.
72.
Salmi M, Kalimo K, Jalkanen S. Induction and
function of vascular adhesion protein-1 at sites of
inflammation. J Exp Med. 1993;178:2255-2260.
73. Salmi M, Jalkanen S. Different forms of human vascular adhesion protein-1 (VAP-1) in blood vessels in vivo and in cultured endothelial cells: implications for lymphocyte-endothelial cell adhesion models. Eur J Immunol. 1995;25:2803-2812.[Medline] [Order article via Infotrieve]
74. Picker LJ, Kishimoto TK, Smith CW, Warnock RA, Butcher EC. ELAM-1 is an adhesion molecule for skin-homing T cells. Nature. 1991;349:796-799.[Medline] [Order article via Infotrieve]
75. Picker LJ, Michie SA, Rott LS, Butcher EC. A unique phenotype of skin-associated lymphocytes in humans: preferential expression of the HECA-452 epitope by benign and malignant T cells at cutaneous sites. Am J Pathol. 1990;136:1053-1068.[Abstract]
76. Arvilommi AM, Salmi M, Kalimo K, Jalkanen S. Lymphocyte binding to vascular endothelium in inflamed skin revisited: a central role for vascular adhesion protein-1 (VAP-1). Eur J Immunol. 1996;26:825-833.[Medline] [Order article via Infotrieve]
77. Abbound CN. Human bone marrow microvascular endothelial cells: elusive cells with unique structural and functional properties. Exp Hematol. 1995;23:1-3.[Medline] [Order article via Infotrieve]
78.
Fennie C, Cheng J, Dowbenko D, Young P, Lasky
LA. CD34+ endothelial cell lines derived from
murine yolk sac induce the proliferation and differentiation of yolk
sac CD34+ hematopoietic progenitors. Blood. 1995;86:4454-4467.
79.
Young PE, Baumhueter S, Lasky LA. The
sialomucin CD34 is expressed on hematopoietic cells and blood vessels
during murine development. Blood. 1995;85:96-105.
80.
Huang H, Auerbach R. Identification and
characterization of hematopoietic stem cells from the yolk sac of the
early mouse embryo. Proc Natl Acad Sci U S A. 1993;90:10110-10114.
81.
Rafii S, Shapiro F, Rimarachin J, Nachman RL, Ferris
B, Weksler B, Moore MA, Asch AS. Isolation and characterization
of human bone marrow microvascular endothelial cells:
hematopoietic progenitor cell adhesion. Blood. 1994;84:10-19.
82.
Rafii S, Shapiro F, Pettengell R, Ferris B, Nachman
RL, Moore MA, Asch AS. Human bone marrow microvascular
endothelial cells support long-term proliferation and
differentiation of myeloid and megakaryocytic progenitors.
Blood. 1995;86:3353-3363.
83. Sieff CA, Niemeyer CM, Faller DV. The production of hematopoietic growth factors by endothelial accessory cells. Blood Cells. 1987;13:65-74.[Medline] [Order article via Infotrieve]
84. Bussolino F, Bocchietto E, Silvagno F, Soldi R, Arese M, Mantovani A. Actions of molecules which regulate hemopoiesis on endothelial cells: memoirs of common ancestors? Pathol Res Pract. 1994;190:834-839.[Medline] [Order article via Infotrieve]
85.
Papayannopoulou T, Craddock C, Nakamoto B, Priestley
GV, Wolf NS. The VLA4/VCAM-1 adhesion pathway defines
contrasting mechanisms of lodgement of transplanted murine hemopoietic
progenitors between bone marrow and spleen. Proc Natl
Acad Sci U S A. 1995;92:9647-9651.
86. Wilkins BS, Jones DB. Vascular networks within the stroma of human long-term bone marrow cultures. J Pathol. 1995;177:295-301.[Medline] [Order article via Infotrieve]
87.
Jacobsen K, Kravitz J, Kincade PW, Osmond DG.
Adhesion receptors on bone marrow stromal cells: in vivo expression of
vascular cell adhesion molecule-1 by reticular cells and sinusoidal
endothelium in normal and gamma-irradiated
mice. Blood. 1996;87:73-82.
88. Schweitzer KM, Drager AM, van der Valk P, Thijsen SF, Zevenbergen A, Theijsmeijer AP, van der Schoot CE, Langenhuijsen MM. Constitutive expression of E-selectin and vascular cell adhesion molecule-1 on endothelial cells of hematopoietic tissues. Am J Pathol. 1996;148:165-175.[Abstract]
89. Risau W, Wolburg H. Development of the blood-brain barrier. Trends Neurosci. 1990;13:174-178.[Medline] [Order article via Infotrieve]
90. Staddon JM, Rubin LL. Cell adhesion, cell junctions and the blood-brain barrier. Curr Opin Neurobiol. 1996;6:622-627.[Medline] [Order article via Infotrieve]
91. Joo F. Endothelial cells of the brain and other organ systems: some similarities and differences. Prog Neurobiol. 1996;48:255-273.[Medline] [Order article via Infotrieve]
92. Wolburg H, Neuhaus J, Kniesel U, Krauss B, Schmid EM, Ocalan M, Farrell C, Risau W. Modulation of tight junction structure in blood-brain barrier endothelial cells: effects of tissue culture, second messengers and cocultured astrocytes. J Cell Sci. 1994;107:1347-1357.[Abstract]
93. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CA, van der Valk MA, Robanus-Maandag EC, te Riele HP. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell. 1994;77:491-502.[Medline] [Order article via Infotrieve]
94. Qin Y, Sato TN. Mouse multidrug resistance 1a/3 gene is the earliest known endothelial cell differentiation marker during blood-brain barrier development. Dev Dyn. 1995;202:172-180.[Medline] [Order article via Infotrieve]
95. Maher F, Vannucci SJ, Simpson IA. Glucose transporter proteins in brain. FASEB J. 1994;8:1003-1011.[Abstract]
96. Janzer RC, Raff MC. Astrocytes induce blood-brain barrier properties in endothelial cells. Nature. 1987;325:253-257.[Medline] [Order article via Infotrieve]
97. Achen MG, Clauss M, Schnurch H, Risau W. The non-receptor tyrosine kinase Lyn is localised in the developing murine blood-brain barrier. Differentiation. 1995;59:15-24.[Medline] [Order article via Infotrieve]
98. Holash HA, Noden DM, Stewart PA. Re-evaluating the role of astrocytes in blood-brain barrier induction. Dev Dyn. 1993;197:14-25.[Medline] [Order article via Infotrieve]
99.
Breier G, Breviario F, Caveda L, Berthier R, Schnurch
H, Gotsch U, Vestweber D, Risau W, Dejana E. Molecular cloning
and expression of murine vascular endothelial-cadherin
in early stage development of cardiovascular
system. Blood. 1996;87:630-641.
100. Hallmann R, Mayer DN, Berg EL, Broermann R, Butcher EC. Novel mouse endothelial cell surface marker is suppressed during differentiation of the blood brain barrier. Dev Dyn. 1995;202:325-332.[Medline] [Order article via Infotrieve]
101. Coomber BL, Stewart PA, Hayakawa K, Farrell CL, Del Maestro RF. Quantitative morphology of human glioblastoma multiforme microvessels: structural basis of blood-brain barrier defect. J Neurooncol. 1987;5:299-307.[Medline] [Order article via Infotrieve]
102. Ferrara N. Vascular endothelial growth factor. Trends Cardiovasc Med. 1993;3:244-250.
103. Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature. 1994;367:576-579.[Medline] [Order article via Infotrieve]
104. Breier G, Risau W. Angiogenesis in the developing brain and in brain tumours. Trends Exp Med. 1996;6:362-376.
105. Folkman J. Tumor angiogenesis. In: Holland JF, Bast RC, Morton DL, Frei E, Kufe DW, Weichselbaum RR, eds. Cancer Medicine. Baltimore, Md: Williams & Wilkins; 1996:181-204.
106.
Folkman J, Klagsburn M. Angiogenic
factors. Science. 1987;235:442-447.
107.
Pepper MS. Manipulating angiogenesis: from
basic science to the bedside. Arterioscler Thromb Vasc
Biol. 1997;17:605-619.
108. Fan TP, Jaggar R, Bicknell R. Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy. Trends Pharmacol Sci. 1995;16:57-66.[Medline] [Order article via Infotrieve]
109. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 1995;146:1029-1039.[Abstract]
110. Roberts WG, Palade GE. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci. 1995;108:2369-2379.[Abstract]
111. Fong GH, Rossant J, Gertsenstein M, Breitman ML. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature. 1995;376:66-70.[Medline] [Order article via Infotrieve]
112. Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML, Schuh AC. Failure of blood-island formation and vasculogenesis in Flk-1–deficient mice. Nature. 1995;376:62-66.[Medline] [Order article via Infotrieve]
113. Sato TN, Tozawa Y, Deutsch U, Wolburg Buchholz K, Fujiwara Y, Gendron Maguire M, Gridley T, Wolburg H, Risau W, Qin Y. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature. 1995;376:70-74.[Medline] [Order article via Infotrieve]
114. Brooks PC, Stromblad S, Sanders LC, von Schalscha TL, Aimes RT, Stetler Stevenson WG, Quigley JP, Cheresh DA. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell. 1996;85:683-693.[Medline] [Order article via Infotrieve]
115. Castellani P, Viale G, Dorcaratto A, Nicolo G, Kaczmarek J, Querze G, Zardi L. The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. Int J Cancer. 1994;59:612-618. Published erratum appears in Int J Cancer. 1995;62:118.[Medline] [Order article via Infotrieve]
116. Melder RJ, Koenig GC, Witwer BP, Safabakhsh N, Munn LL, Jain RK. During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nat Med. 1996;2:992-997.[Medline] [Order article via Infotrieve]
117. Enzinger FM, Weiss SW. Benign tumors and tumor like lesions of blood vessels. In: Soft Tissue Tumors. St Louis, Mo: CV Mosby; 1988:489-532.
118. Martin Padura I, De Castellarnau C, Uccini S, Pilozzi E, Natali PG, Nicotra MR, Ughi F, Azzolini C, Dejana E, Ruco L. Expression of VE (vascular endothelial)-cadherin and other endothelial-specific markers in haemangiomas. J Pathol. 1995;175:51-57.[Medline] [Order article via Infotrieve]
119.
Takeichi M. Cadherin cell adhesion receptors as
a morphogenetic regulator. Science. 1991;251:1451-1455.
120. Uccini S, Ruco LP, Monardo F, Stoppacciaro A, Dejana E, La Parola IL, Cerimele D, Baroni CD. Co-expression of endothelial cell and macrophage antigens in Kaposi's sarcoma cells. J Pathol. 1994;173:23-31.[Medline] [Order article via Infotrieve]
121.
Ensoli B, Nakamura S, Salahuddin SZ, Biberfeld P,
Larsson L, Beaver B, Wong Staal F, Gallo RC. AIDS–Kaposi's
sarcoma–derived cells express cytokines with autocrine and
paracrine growth effects. Science. 1989;243:223-226.
122. Brown LF, Tognazzi K, Dvorak HF, Harrist TJ. Strong expression of kinase insert domain-containing receptor, a vascular permeability factor/vascular endothelial growth factor receptor in AIDS-associated Kaposi's sarcoma and cutaneous angiosarcoma. Am J Pathol. 1996;148:1065-1074.[Abstract]
123. Kraling BM, Razon MJ, Boon LM, Zurakowski D, Seachord C, Darveau RP, Mulliken JB, Corless CL, Bischoff J. E-selectin is present in proliferating endothelial cells in human hemangiomas. Am J Pathol. 1996;148:1181-1191.[Abstract]
124. Montesano R, Pepper MS, Mohle Steinlein U, Risau W, Wagner EF, Orci L. Increased proteolytic activity is responsible for the aberrant morphogenetic behavior of endothelial cells expressing the middle T oncogene. Cell. 1990;62:435-445.[Medline] [Order article via Infotrieve]
125. Vikkula M, Boon LM, Carraway KL III, Calvert JT, Diamonti AJ, Goumnerov B, Pasyk KA, Marchuk DA, Warman ML, Cantley LC, Mulliken JB, Olsen BR. Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. Cell. 1996;87:1181-1190.[Medline] [Order article via Infotrieve]
126. Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, Ryan TE, Bruno J, Radziejewski C, Maisopierre PC, Yancopoulos GD. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell. 1996;87:1161-1169.[Medline] [Order article via Infotrieve]
127. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato TN, Yancopoulos GD. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell. 1996;87:1171-1180.[Medline] [Order article via Infotrieve]
128. McAllister KA, Grogg KM, Johnson DW, Gallione CJ, Baldwin MA, Jackson CE, Helmbold EA, Markel DS, McKinnon WC, Murrell J. Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet. 1994;8:345-351.[Medline] [Order article via Infotrieve]
129. Johnson DW, Berg JN, Baldwin MA, Gallione CJ, Marondel I, Yoon SJ, Stenzel TT, Speer M, Pericak Vance MA, Diamond A, Guttmacher AE, Jackson CE, Attisano L, Kucherlapati R, Porteous ME, Marchuk DA. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet. 1996;13:189-195.[Medline] [Order article via Infotrieve]
130.
Patterson C, Perrella MA, Hsieh CM, Yoshizumi M, Lee
ME, Haber E. Cloning and functional analysis of
the promoter for KDR/flk-1, a receptor for vascular
endothelial growth factor. J Biol
Chem. 1995;270:23111-23118.
131.
Morishita K, Johnson DE, Williams LT. A novel
promoter for vascular endothelial growth factor
receptor (flt-1) that confers endothelial-specific gene
expression. J Biol Chem. 1995;270:27948-27953.
132. Schlaeger TM, Qin Y, Fujiwara Y, Magram J, Sato TN. Vascular endothelial cell lineage-specific promoter in transgenic mice. Development. 1995;121:1089-1098.[Abstract]
133.
Aird WC, Jahroudi N, Weiler Guettler H, Rayburn HB,
Rosenberg RD. Human von Willebrand factor gene sequences
target expression to a subpopulation of endothelial
cells in transgenic mice. Proc Natl Acad Sci
U S A. 1995;92:4567-4571.
134.
Paul M, Zintz M, Bocker W, Dyer M.
Characterization and functional analysis of the rat
endothelin-1 promoter. Hypertension. 1995;25:683-693.
135. Almendro N, Bellòn T, Rius C, Lastres P, Langa C, Corbì A, Bernabéu C. Cloning of the human platelet endothelial cell adhesion molecule-1 promoter and its tissue-specific expression. J Immunol. 1996;157:5411-5421.[Abstract]
This article has been cited by other articles:
 |
|
 |
|
  A. Jiang, W. Hu, H. Meng, H. Gao, and X. Qiao Loss of VLDL Receptor Activates Retinal Vascular Endothelial Cells and Promotes Angiogenesis Invest. Ophthalmol. Vis. Sci., February 1, 2009; 50(2): 844 - 850. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Marmon, J. Hinchey, P. Oh, M. Cammer, C. J. de Almeida, L. Gunther, C. S. Raine, and M. P. Lisanti Caveolin-1 Expression Determines the Route of Neutrophil Extravasation through Skin Microvasculature Am. J. Pathol., February 1, 2009; 174(2): 684 - 692. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Mariappan, J. Winkler, S. Chen, H. Schulz, J. Hescheler, and A. Sachinidis Transcriptional profiling of CD31(+) cells isolated from murine embryonic stem cells. Genes Cells, February 1, 2009; 14(2): 243 - 260. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. da Silva Meirelles, A. I. Caplan, and N. B. Nardi In Search of the In Vivo Identity of Mesenchymal Stem Cells Stem Cells, September 1, 2008; 26(9): 2287 - 2299. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Mikhailov, A. Sokolovskaya, G. G. Yegutkin, H. Amdahl, A. West, H. Yagita, R. Lahesmaa, L. F. Thompson, S. Jalkanen, D. Blokhin, et al. CD73 Participates in Cellular Multiresistance Program and Protects against TRAIL-Induced Apoptosis J. Immunol., July 1, 2008; 181(1): 464 - 475. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Acevedo, I. Londono, M. Oubaha, L. Ghitescu, and M. Bendayan Glomerular CD34 Expression in Short- and Long-term Diabetes J. Histochem. Cytochem., June 1, 2008; 56(6): 605 - 614. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Godoy, A. Watts, P. Sotomayor, V. P. Montecinos, W. J. Huss, S. A. Onate, and G. J. Smith Androgen Receptor Is Causally Involved in the Homeostasis of the Human Prostate Endothelial Cell Endocrinology, June 1, 2008; 149(6): 2959 - 2969. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. F. Pla, C. Grange, S. Antoniotti, C. Tomatis, A. Merlino, B. Bussolati, and L. Munaron Arachidonic Acid-Induced Ca2+ Entry Is Involved in Early Steps of Tumor Angiogenesis Mol. Cancer Res., April 1, 2008; 6(4): 535 - 545. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Kleinschmidt, M. Nassiri, M. S. Stitt, K. Wasserloos, S. C. Watkins, B. R. Pitt, and N. Jahroudi Sequences in Intron 51 of the von Willebrand Factor Gene Target Promoter Activation to a Subset of Lung Endothelial Cells in Transgenic Mice J. Biol. Chem., February 1, 2008; 283(5): 2741 - 2750. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Doublier, M. Ceretto, E. Lupia, S. Bravo, B. Bussolati, and G. Camussi The Proangiogenic Phenotype of Tumor-Derived Endothelial Cells is Reverted by the Overexpression of Platelet-Activating Factor Acetylhydrolase Clin. Cancer Res., October 1, 2007; 13(19): 5710 - 5718. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. D. Nascimento, M. A. F. Hayashi, A. Kerkis, V. Oliveira, E. B. Oliveira, G. Radis-Baptista, H. B. Nader, T. Yamane, I. L. dos Santos Tersariol, and I. Kerkis Crotamine Mediates Gene Delivery into Cells through the Binding to Heparan Sulfate Proteoglycans J. Biol. Chem., July 20, 2007; 282(29): 21349 - 21360. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. F. Davies Endothelial Mechanisms of Flow-Mediated Athero-Protection and Susceptibility Circ. Res., July 6, 2007; 101(1): 10 - 12. [Full Text] [PDF]
|
|
|
|
|
|
S. Danese, E. Dejana, and C. Fiocchi Immune Regulation by Microvascular Endothelial Cells: Directing Innate and Adaptive Immunity, Coagulation, and Inflammation J. Immunol., May 15, 2007; 178(10): 6017 - 6022. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. R. Langley and I. J. Fidler Tumor Cell-Organ Microenvironment Interactions in the Pathogenesis of Cancer Metastasis Endocr. Rev., May 1, 2007; 28(3): 297 - 321. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. C. Aird Phenotypic Heterogeneity of the Endothelium: I. Structure, Function, and Mechanisms Circ. Res., February 2, 2007; 100(2): 158 - 173. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Robert, M.-J. Jacobin-Valat, D. Daret, S. Miraux, A. T. Nurden, J.-M. Franconi, and G. Clofent-Sanchez Identification of Human scFvs Targeting Atherosclerotic Lesions: SELECTION BY SINGLE ROUND IN VIVO PHAGE DISPLAY J. Biol. Chem., December 29, 2006; 281(52): 40135 - 40143. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. L. T. Ballard, J. M. Holm, and J. M. Edelberg Quantitative PCR-based approach for rapid phage display analysis: a foundation for high throughput vascular proteomic profiling Physiol Genomics, September 14, 2006; 26(3): 202 - 208. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Tripathi, D. J. Sullivan, and M. F. Stins Plasmodium falciparum-Infected Erythrocytes Increase Intercellular Adhesion Molecule 1 Expression on Brain Endothelium through NF-{kappa}B. Infect. Immun., June 1, 2006; 74(6): 3262 - 3270. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Cassoni, T. Marrocco, B. Bussolati, E. Allia, L. Munaron, A. Sapino, and G. Bussolati Oxytocin Induces Proliferation and Migration in Immortalized Human Dermal Microvascular Endothelial Cells and Human Breast Tumor-Derived Endothelial Cells Mol. Cancer Res., June 1, 2006; 4(6): 351 - 359. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Despars and H. C. O'Neill Splenic endothelial cell lines support development of dendritic cells from bone marrow. Stem Cells, June 1, 2006; 24(6): 1496 - 1504. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Korff, G. Dandekar, D. Pfaff, T. Fuller, W. Goettsch, H. Morawietz, F. Schaffner, and H. G. Augustin Endothelial EphrinB2 Is Controlled by Microenvironmental Determinants and Associates Context-Dependently With CD31 Arterioscler. Thromb. Vasc. Biol., March 1, 2006; 26(3): 468 - 474. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. C. Wassmer, V. Combes, F. J. Candal, I. Juhan-Vague, and G. E. Grau Platelets Potentiate Brain Endothelial Alterations Induced by Plasmodium falciparum Infect. Immun., January 1, 2006; 74(1): 645 - 653. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. F. Costa, M. Balcells, E. R. Edelman, L. M. Nadler, and A. A. Cardoso Proangiogenic stimulation of bone marrow endothelium engages mTOR and is inhibited by simultaneous blockade of mTOR and NF-{kappa}B Blood, January 1, 2006; 107(1): 285 - 292. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Zhang, H.-C. Sun, Y. Xu, K.-Z. Zhang, L. Wang, L.-X. Qin, W.-Z. Wu, Y.-K. Liu, S.-L. Ye, and Z.-Y. Tang Overexpression of Platelet-Derived Growth Factor Receptor {alpha} in Endothelial Cells of Hepatocellular Carcinoma Associated with High Metastatic Potential Clin. Cancer Res., December 15, 2005; 11(24): 8557 - 8563. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Stevens Molecular and Cellular Determinants of Lung Endothelial Cell Heterogeneity Chest, December 1, 2005; 128(6_suppl): 558S - 564S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P.-L. Tremblay, F. Berthod, L. Germain, and F. A. Auger In Vitro Evaluation of the Angiostatic Potential of Drugs Using an Endothelialized Tissue-Engineered Connective Tissue J. Pharmacol. Exp. Ther., November 1, 2005; 315(2): 510 - 516. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. R. White, M. W. Hamade, K. Siami, M. M. Chang, A. Mangalwadi, J. A. Frangos, and W. J. Pearce Maturation enhances fluid shear-induced activation of eNOS in perfused ovine carotid arteries Am J Physiol Heart Circ Physiol, November 1, 2005; 289(5): H2220 - H2227. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Zhang, J. A. Hoffman, and E. Ruoslahti Molecular Profiling of Heart Endothelial Cells Circulation, September 13, 2005; 112(11): 1601 - 1611. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Holmen, P. Stjarne, and S. Sumitran-Holgersson Heterogeneity of Human Nasal Vascular and Sinusoidal Endothelial Cells from the Inferior Turbinate Am. J. Respir. Cell Mol. Biol., January 1, 2005; 32(1): 18 - 27. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Zaitseva, D. S. Yue, J. A. Katzenellenbogen, P. A. W. Rogers, and C. E. Gargett Estrogen Receptor-{alpha} Agonists Promote Angiogenesis in Human Myometrial Microvascular Endothelial Cells Reproductive Sciences, December 1, 2004; 11(8): 529 - 535. [Abstract] [PDF]
|
|
|
|
 |
|
 J. Heidemann, H. Ogawa, P. Rafiee, N. Lugering, C. Maaser, W. Domschke, D. G. Binion, and M. B. Dwinell Mucosal angiogenesis regulation by CXCR4 and its ligand CXCL12 expressed by human intestinal microvascular endothelial cells Am J Physiol Gastrointest Liver Physiol, June 1, 2004; 286(6): G1059 - G1068. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D.-A. Lacorre, E. S. Baekkevold, I. Garrido, P. Brandtzaeg, G. Haraldsen, F. Amalric, and J.-P. Girard Plasticity of endothelial cells: rapid dedifferentiation of freshly isolated high endothelial venule endothelial cells outside the lymphoid tissue microenvironment Blood, June 1, 2004; 103(11): 4164 - 4172. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Lazrak, V. Deleuze, D. Noel, D. Haouzi, E. Chalhoub, C. Dohet, I. Robbins, and D. Mathieu The bHLH TAL-1/SCL regulates endothelial cell migration and morphogenesis J. Cell Sci., March 1, 2004; 117(7): 1161 - 1171. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Pellegrino, E. Furmaniak-Kazmierczak, J. C. LeBlanc, T. Cho, K. Cao, S. M. Marcovina, M. B. Boffa, G. P. Cote, and M. L. Koschinsky The Apolipoprotein(a) Component of Lipoprotein(a) Stimulates Actin Stress Fiber Formation and Loss of Cell-Cell Contact in Cultured Endothelial Cells J. Biol. Chem., February 20, 2004; 279(8): 6526 - 6533. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Moccia, C. Frost, R. Berra-Romani, F. Tanzi, and D. J. Adams Expression and function of neuronal nicotinic ACh receptors in rat microvascular endothelial cells Am J Physiol Heart Circ Physiol, February 1, 2004; 286(2): H486 - H491. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Eikemo, O. F. M. Sellevold, and V. Videm Markers for endothelial activation during open heart surgery Ann. Thorac. Surg., January 1, 2004; 77(1): 214 - 219. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Rafiee, H. Ogawa, J. Heidemann, M. S. Li, M. Aslam, T. H. Lamirand, P. J. Fisher, S. J. Graewin, M. B. Dwinell, C. P. Johnson, et al. Isolation and characterization of human esophageal microvascular endothelial cells: mechanisms of inflammatory activation Am J Physiol Gastrointest Liver Physiol, December 1, 2003; 285(6): G1277 - G1292. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Favre, M. Mancuso, K. Maas, J. W. McLean, P. Baluk, and D. M. McDonald Expression of genes involved in vascular development and angiogenesis in endothelial cells of adult lung Am J Physiol Heart Circ Physiol, November 1, 2003; 285(5): H1917 - H1938. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. R. Langley, K. M. Ramirez, R. Z. Tsan, M. Van Arsdall, M. B. Nilsson, and I. J. Fidler Tissue-specific Microvascular Endothelial Cell Lines from H-2Kb-tsA58 Mice for Studies of Angiogenesis and Metastasis Cancer Res., June 1, 2003; 63(11): 2971 - 2976. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C. Polacek, A. G. Passerini, C. Shi, N. M. Francesco, E. Manduchi, G. R. Grant, S. Powell, H. Bischof, H. Winkler, C. J. Stoeckert Jr., et al. Fidelity and enhanced sensitivity of differential transcription profiles following linear amplification of nanogram amounts of endothelial mRNA Physiol Genomics, April 16, 2003; 13(2): 147 - 156. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Silverman, D. O. Zamora, Y. Pan, P. V. Texeira, S.-H. Baek, S. R. Planck, and J. T. Rosenbaum Constitutive and Inflammatory Mediator-Regulated Fractalkine Expression in Human Ocular Tissues and Cultured Cells Invest. Ophthalmol. Vis. Sci., April 1, 2003; 44(4): 1608 - 1615. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Peng and N. Jahroudi The NFY Transcription Factor Inhibits von Willebrand Factor Promoter Activation in Non-endothelial Cells through Recruitment of Histone Deacetylases J. Biol. Chem., February 28, 2003; 278(10): 8385 - 8394. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Heidemann, H. Ogawa, M. B. Dwinell, P. Rafiee, C. Maaser, H. R. Gockel, M. F. Otterson, D. M. Ota, N. Lugering, W. Domschke, et al. Angiogenic Effects of Interleukin 8 (CXCL8) in Human Intestinal Microvascular Endothelial Cells Are Mediated by CXCR2 J. Biol. Chem., February 28, 2003; 278(10): 8508 - 8515. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Paszkowiak and A. Dardik Arterial Wall Shear Stress: Observations from the Bench to the Bedside Vascular and Endovascular Surgery, January 1, 2003; 37(1): 47 - 57. [Abstract] [PDF]
|
|
|
|
 |
|
 V. A. Patel, A. Logan, J. C. Watkinson, S. Uz-Zaman, M. C. Sheppard, J. D. Ramsden, and M. C. Eggo Isolation and characterization of human thyroid endothelial cells Am J Physiol Endocrinol Metab, January 1, 2003; 284(1): E168 - E176. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Usui, T. Murai, T. Tanaka, K. Yamaguchi, D. Nagakubo, C. M. Lee, M. Kiyomi, S. Tamura, Y. Matsuzawa, and M. Miyasaka Characterization of mac25/angiomodulin expression by high endothelial venule cells in lymphoid tissues and its identification as an inducible marker for activated endothelial cells Int. Immunol., November 1, 2002; 14(11): 1273 - 1282. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G.C. Weston, I. Haviv, and P.A.W. Rogers Microarray analysis of VEGF-responsive genes in myometrial endothelial cells Mol. Hum. Reprod., September 1, 2002; 8(9): 855 - 863. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. C. Aird, S. B. Glueck, V. J. Dzau, and R. E. Pratt Separating the wheat from the chaff: Focus on "In silico data filtering to identify new angiogenesis targets from a large in vitro gene profile data set" Physiol Genomics, July 12, 2002; 10(1): 1 - 3. [Full Text] [PDF]
|
|
|
|
|
|
D. Wang, R. E. Lehman, D. B. Donner, M. R. Matli, R. S. Warren, and M. L. Welton Expression and endocytosis of VEGF and its receptors in human colonic vascular endothelial cells Am J Physiol Gastrointest Liver Physiol, June 1, 2002; 282(6): G1088 - G1096. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Peng and N. Jahroudi The NFY transcription factor functions as a repressor and activator of the von Willebrand factor promoter Blood, April 1, 2002; 99(7): 2408 - 2417. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Papapetropoulos, S. Andreopoulos, C. Y. Go, A. Hoque, L. C. Fuchs, and J. D. Catravas Regulation of the nitric oxide synthase-nitric oxide- cGMP pathway in rat mesenteric endothelial cells J Appl Physiol, December 1, 2001; 91(6): 2553 - 2560. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Arrate, J. M. Rodriguez, T. M. Tran, T. A. Brock, and S. A. Cunningham Cloning of Human Junctional Adhesion Molecule 3 (JAM3) and Its Identification as the JAM2 Counter-receptor J. Biol. Chem., November 30, 2001; 276(49): 45826 - 45832. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Silverman, D. O. Zamora, Y. Pan, P. V. Texeira, S. R. Planck, and J. T. Rosenbaum Cell Adhesion Molecule Expression in Cultured Human Iris Endothelial Cells Invest. Ophthalmol. Vis. Sci., November 1, 2001; 42(12): 2861 - 2866. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. J. Hutley, A. C. Herington, W. Shurety, C. Cheung, D. A. Vesey, D. P. Cameron, and J. B. Prins Human adipose tissue endothelial cells promote preadipocyte proliferation Am J Physiol Endocrinol Metab, November 1, 2001; 281(5): E1037 - E1044. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. MURCIANO, D. WIN HARSHAW, L. GHITESCU, S. M. DANILOV, and V. R. MUZYKANTOV Vascular Immunotargeting to Endothelial Surface in a Specific Macrodomain in Alveolar Capillaries Am. J. Respir. Crit. Care Med., October 1, 2001; 164(7): 1295 - 1302. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Sun, M. Vitolo, and A. Passaniti Runt-related Gene 2 in Endothelial Cells: Inducible Expression and Specific Regulation of Cell Migration and Invasion Cancer Res., July 1, 2001; 61(13): 4994 - 5001. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Danilov, V. D. Gavrilyuk, F. E. Franke, K. Pauls, D. W. Harshaw, T. D. McDonald, D. J. Miletich, and V. R. Muzykantov Lung uptake of antibodies to endothelial antigens: key determinants of vascular immunotargeting Am J Physiol Lung Cell Mol Physiol, June 1, 2001; 280(6): L1335 - L1347. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Shintani, T. Murohara, H. Ikeda, T. Ueno, K.-i. Sasaki, J. Duan, and T. Imaizumi Augmentation of Postnatal Neovascularization With Autologous Bone Marrow Transplantation Circulation, February 13, 2001; 103(6): 897 - 903. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E Gustafsson, C Brakebusch, K Hietanen, and R Fassler Tie-1-directed expression of Cre recombinase in endothelial cells of embryoid bodies and transgenic mice J. Cell Sci., January 2, 2001; 114(4): 671 - 676. [Abstract] [PDF]
|
|
|
|
 |
|
 R. SALCEDO, J. H. RESAU, D. HALVERSON, E. A. HUDSON, M. DAMBACH, D. POWELL, K. WASSERMAN, and J. J. OPPENHEIM Differential expression and responsiveness of chemokine receptors (CXCR1-3) by human microvascular endothelial cells and umbilical vein endothelial cells FASEB J, October 1, 2000; 14(13): 2055 - 2064. [Abstract] [Full Text]
|
|
|
|
|
|
G. Balconi, R. Spagnuolo, and E. Dejana Development of Endothelial Cell Lines From Embryonic Stem Cells : A Tool for Studying Genetically Manipulated Endothelial Cells In Vitro Arterioscler. Thromb. Vasc. Biol., June 1, 2000; 20(6): 1443 - 1451. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T.-Y. HUANG, T.-F. CHU, H.-I. CHEN, and C. J. JEN Heterogeneity of [Ca2+]i signaling in intact rat aortic endothelium FASEB J, April 1, 2000; 14(5): 797 - 804. [Abstract] [Full Text]
|
|
|
|
 |
|
 C.E. Gargett, K. Bucak, and P.A.W. Rogers Isolation, characterization and long-term culture of human myometrial microvascular endothelial cells Hum. Reprod., February 1, 2000; 15(2): 293 - 301. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-P. Girard, E. S. Baekkevold, T. Yamanaka, G. Haraldsen, P. Brandtzaeg, and F. Amalric Heterogeneity of Endothelial Cells : The Specialized Phenotype of Human High Endothelial VenulesCharacterized by Suppression Subtractive Hybridization Am. J. Pathol., December 1, 1999; 155(6): 2043 - 2055. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Ando, T. Kubin, W. Schaper, and J. Schaper Cardiac microvascular endothelial cells express alpha -smooth muscle actin and show low NOS III activity Am J Physiol Heart Circ Physiol, May 1, 1999; 276(5): H1755 - H1768. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Ross Atherosclerosis -- An Inflammatory Disease N. Engl. J. Med., January 14, 1999; 340(2): 115 - 126. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Korff and H. G. Augustin Integration of Endothelial Cells in Multicellular Spheroids Prevents Apoptosis and Induces Differentiation J. Cell Biol., November 30, 1998; 143(5): 1341 - 1352. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. D'Amico, G. Bianchi, S. Bernasconi, L. Bersani, L. Piemonti, S. Sozzani, A. Mantovani, and P. Allavena Adhesion, Transendothelial Migration, and Reverse Transmigration of In Vitro Cultured Dendritic Cells Blood, July 1, 1998; 92(1): 207 - 214. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||